Immunotherapy, an innovative approach to cancer treatment, is rapidly evolving as a frontline strategy in the fight against a variety of malignancies. This article aims to provide physicians with a comprehensive understanding of the key aspects of immunotherapy, from its basic principles to its clinical applications.
Immunotherapy, also known as biological therapy, is a type of cancer treatment designed to boost the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. The key to immunotherapy lies in its ability to harness the power of the patient's immune system, enabling it to detect and target cancer cells more effectively.
There are several types of immunotherapy, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and CAR T-cell therapy. Monoclonal antibodies are designed to bind to specific targets on cancer cells, while immune checkpoint inhibitors help the immune system recognize and attack cancer cells. Cancer vaccines work by triggering the immune system to attack specific diseases, and CAR T-cell therapy involves modifying T cells to enhance their ability to fight cancer.
Immunotherapy has shown promising results in treating various types of cancer, such as melanoma, lung, kidney, bladder, and head and neck cancers. However, not all patients respond to immunotherapy, and it can cause side effects, including inflammation and immune-related adverse events. Determining which patients will benefit from immunotherapy remains a significant challenge in the field.
Immunotherapy represents a groundbreaking shift in cancer treatment, offering new hope to patients who have previously exhausted all other options. As our understanding of the immune system's role in cancer continues to evolve, it's crucial for physicians to stay abreast of the latest advancements and applications of immunotherapy to provide the best possible care for their patients.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation